Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2021

07.01.2021 | Research Article

Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service

verfasst von: Seif El Hadidi, Carl Vaughan, David Kerins, Stephen Byrne, Ebtissam Darweesh, Margaret Bermingham

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background Guidelines recommend heart failure (HF) patients be treated with multiple medications at doses proven to improve clinical outcomes. Objective To study guideline-led prescribing in an Irish outpatient HF population. Setting Cardiology Outpatient Clinic, Mercy University Hospital, Cork, Ireland. Methods Guideline-led prescribing was assessed using the Guideline Adherence Index (GAI-3), that considered the prescribing of ACE inhibitors and angiotensin receptor blockers; beta-blockers and mineralocorticoid receptor antagonists. The GAI-based target dose was calculated based on the prescription of ≥ 50% of the guideline-recommended target dose of each of the three GAI medications to HF patients with ejection fraction ≤ 40%. High-GAI was achieved by prescription of ≥ 2 GAI medicines. Potentially inappropriate prescribing was assessed using a HF-specific tool. Main outcome measure Heart failure guideline-led prescribing assessed using the GAI-3. Results A total of 127 HF patients, mean age 71.7 ± 13.1 years, were identified in the study. Seventy-one patients had ejection fraction ≤ 40%. Population mean GAI-3 was 65.8%. When contraindications to therapy are considered, the adjusted GAI-3 increased to 72.9%. The target dose GAI was 18.5%. High-GAI management was prescribed to 54 patients (76.1%). A potentially inappropriate medicine in HF was prescribed to 14 (19.7%) patients. Conclusion Most HF patients with ejection fraction ≤ 40% in this setting received optimal guideline-led prescribing however the proportion of patients achieving the target doses of these agents was suboptimal.
Literatur
1.
Zurück zum Zitat McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC 2012 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2012;33:1787–847.PubMedCrossRef McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC 2012 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2012;33:1787–847.PubMedCrossRef
2.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
3.
Zurück zum Zitat Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS, et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19:1414–23.PubMedCrossRef Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS, et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19:1414–23.PubMedCrossRef
4.
Zurück zum Zitat Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–90.PubMedCrossRef Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–90.PubMedCrossRef
5.
Zurück zum Zitat Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.PubMedCrossRef Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.PubMedCrossRef
6.
Zurück zum Zitat Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, et al. Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges. Eur J Heart Fail. 2019;21:286–96.PubMedCrossRef Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, et al. Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges. Eur J Heart Fail. 2019;21:286–96.PubMedCrossRef
7.
Zurück zum Zitat Mogensen UM, Ersboll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail. 2011;13:1216–23.PubMedCrossRef Mogensen UM, Ersboll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail. 2011;13:1216–23.PubMedCrossRef
8.
Zurück zum Zitat Hassanein M, Abdelhamid M, Ibrahim B, Sobhy M, Nasr G, Aboleineen MW, et al. Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry. ESC Heart Fail. 2018;5:1159–64.PubMedPubMedCentralCrossRef Hassanein M, Abdelhamid M, Ibrahim B, Sobhy M, Nasr G, Aboleineen MW, et al. Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry. ESC Heart Fail. 2018;5:1159–64.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Gilstrap LG, Stevenson LW, Small R, Parambi R, Hamershock R, Greenberg J, et al. Reasons for guideline non-adherence at heart failure discharge. J Am Heart Assoc. 2018;7(15):e008789.PubMedPubMedCentralCrossRef Gilstrap LG, Stevenson LW, Small R, Parambi R, Hamershock R, Greenberg J, et al. Reasons for guideline non-adherence at heart failure discharge. J Am Heart Assoc. 2018;7(15):e008789.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167:2695–9.PubMedCrossRef Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167:2695–9.PubMedCrossRef
11.
Zurück zum Zitat Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation. 2015;132:1347–53.PubMedPubMedCentralCrossRef Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation. 2015;132:1347–53.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data. Drugs Aging. 2011;28:575–81.PubMedCrossRef Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data. Drugs Aging. 2011;28:575–81.PubMedCrossRef
13.
Zurück zum Zitat Baron-Franco B, McLean G, Mair FS, Roger VL, Guthrie B, Mercer SW. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e314–20.PubMedPubMedCentralCrossRef Baron-Franco B, McLean G, Mair FS, Roger VL, Guthrie B, Mercer SW. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e314–20.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.PubMedCrossRef Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.PubMedCrossRef
15.
Zurück zum Zitat Bermingham M, Ryder M, Travers B, Edwards N, Lalor L, Kelly D, et al. The St Vincent’s potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail. 2014;16:915–22.PubMedCrossRef Bermingham M, Ryder M, Travers B, Edwards N, Lalor L, Kelly D, et al. The St Vincent’s potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail. 2014;16:915–22.PubMedCrossRef
16.
Zurück zum Zitat Caughey GE, Shakib S, Barratt JD, Roughead EE. Use of medicines that may exacerbate heart failure in older adults: therapeutic complexity of multimorbidity. Drugs Aging. 2019;36:471–9.PubMedCrossRef Caughey GE, Shakib S, Barratt JD, Roughead EE. Use of medicines that may exacerbate heart failure in older adults: therapeutic complexity of multimorbidity. Drugs Aging. 2019;36:471–9.PubMedCrossRef
17.
Zurück zum Zitat Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26:1653–9.PubMedCrossRef Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26:1653–9.PubMedCrossRef
18.
Zurück zum Zitat Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail. 2008;10:1236–45.PubMedCrossRef Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail. 2008;10:1236–45.PubMedCrossRef
19.
Zurück zum Zitat Deticek A, Locatelli I, Roblek T, Mrhar A, Lainscak M. Therapy modifications during hospitalization in patients with chronic heart failure. Eur J Int Med. 2016;29:52–8.CrossRef Deticek A, Locatelli I, Roblek T, Mrhar A, Lainscak M. Therapy modifications during hospitalization in patients with chronic heart failure. Eur J Int Med. 2016;29:52–8.CrossRef
21.
Zurück zum Zitat Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol. 2008;97:244–52.PubMedCrossRef Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol. 2008;97:244–52.PubMedCrossRef
22.
Zurück zum Zitat Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105:441–50.PubMedCrossRef Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105:441–50.PubMedCrossRef
23.
Zurück zum Zitat Barnett NL, Oboh L, Smith K. Patient-centred management of polypharmacy: a process for practice. Eur J Hosp Pharm. 2016;23:113–7.PubMedCrossRef Barnett NL, Oboh L, Smith K. Patient-centred management of polypharmacy: a process for practice. Eur J Hosp Pharm. 2016;23:113–7.PubMedCrossRef
24.
Zurück zum Zitat El Hadidi S, Darweesh E, Byrne S, Bermingham M. A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2018;27:685–94.PubMedCrossRef El Hadidi S, Darweesh E, Byrne S, Bermingham M. A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2018;27:685–94.PubMedCrossRef
25.
Zurück zum Zitat Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175:83–9.PubMedCrossRef Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175:83–9.PubMedCrossRef
26.
Zurück zum Zitat Frankenstein L, Remppis A, Fluegel A, Doesch A, Katus HA, Senges J, et al. The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail. 2010;12:574–80.PubMedCrossRef Frankenstein L, Remppis A, Fluegel A, Doesch A, Katus HA, Senges J, et al. The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail. 2010;12:574–80.PubMedCrossRef
27.
Zurück zum Zitat Oertle M, Bal R. Understanding non-adherence in chronic heart failure: a mixed-method case study. Qual Saf Health Care. 2010;19(6):e37.PubMed Oertle M, Bal R. Understanding non-adherence in chronic heart failure: a mixed-method case study. Qual Saf Health Care. 2010;19(6):e37.PubMed
28.
Zurück zum Zitat Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20:1326–34.PubMedCrossRef Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20:1326–34.PubMedCrossRef
29.
Zurück zum Zitat Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail. 2017;19:1284–93.PubMedCrossRef Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail. 2017;19:1284–93.PubMedCrossRef
30.
Zurück zum Zitat Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef
32.
Zurück zum Zitat Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail. 2016;4:109–15.PubMedCrossRef Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail. 2016;4:109–15.PubMedCrossRef
33.
Zurück zum Zitat Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.PubMedCrossRef Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.PubMedCrossRef
34.
Zurück zum Zitat Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.PubMedCrossRef Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.PubMedCrossRef
35.
Zurück zum Zitat Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7:350–8.PubMedPubMedCentralCrossRef Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7:350–8.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement? J Am Coll Cardiol. 2017;69:2542–50.PubMedCrossRef Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement? J Am Coll Cardiol. 2017;69:2542–50.PubMedCrossRef
38.
Zurück zum Zitat Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6:235–43.PubMedCrossRef Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6:235–43.PubMedCrossRef
39.
Zurück zum Zitat Tebbe U, Tschope C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014;103:665–73.PubMedCrossRef Tebbe U, Tschope C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014;103:665–73.PubMedCrossRef
40.
Zurück zum Zitat Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866.PubMedPubMedCentralCrossRef Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, et al. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013;51:901–7.PubMedPubMedCentralCrossRef Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, et al. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013;51:901–7.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Mockler M, O’Loughlin C, Murphy N, Ryder M, Conlon C, McDonald KM, et al. Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol. 2009;103:834–8.PubMedCrossRef Mockler M, O’Loughlin C, Murphy N, Ryder M, Conlon C, McDonald KM, et al. Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol. 2009;103:834–8.PubMedCrossRef
43.
Zurück zum Zitat Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328–42.PubMedCrossRef Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328–42.PubMedCrossRef
44.
Zurück zum Zitat Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33:314–24.PubMedCrossRef Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33:314–24.PubMedCrossRef
45.
Zurück zum Zitat Bhat S, Kansal M, Kondos GT, Groo V. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52:724–32.PubMedCrossRef Bhat S, Kansal M, Kondos GT, Groo V. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52:724–32.PubMedCrossRef
Metadaten
Titel
Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service
verfasst von
Seif El Hadidi
Carl Vaughan
David Kerins
Stephen Byrne
Ebtissam Darweesh
Margaret Bermingham
Publikationsdatum
07.01.2021
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2021
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01220-z

Weitere Artikel der Ausgabe 4/2021

International Journal of Clinical Pharmacy 4/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.